Company intelligence / Profile preview

Athera Biotechnologies AB

Stockholm, Stockholm County, Swedenca.linkedin.com ↗

Ownership: Private
Employees: ~8
Development stage: Phase 2

Overview

Athera completed a Phase 2 study with its lead candidate PC-mAb. The last patient was dosed in April 2020. The company is developing targeted anti-inflammatory biological drugs for prevention and treatment of immunovascular disease.

Therapeutic areas: Cardiovascular
Modalities: Monoclonal antibodiesBiological drugs
Industry: Biotech

Drug pipeline

2 assets

ATH3G10

Phase 2

Indications: Cardiovascular disease, Myocardial infarction

1 more asset in the full pipeline.

Request access →

Partnerships

Dyax Corp.European Union FP7 program (CARDIMMUN consortium)Leiden University Medical Center (LUMC)Turku PET CenterClinical Trial Consultants (CTC)Smerud Medical Research

Beyond the preview

Go deeper on Athera Biotechnologies AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Athera Biotechnologies AB.

Explore the full profile